OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 64 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
Follow-Up Questions
ORPOF の株価パフォーマンスは？
ORPOF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
OSE Immunotherapeutics SA の主な事業テーマや業界は？
OSE Immunotherapeutics SA は Biotechnology 業界、セクターは Health Care に属しています。
